– USA, CA – Tivic Health Systems, Inc. (Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, announced the appointment of Christina Valauri to its Board of Directors, effective July 1, 2024.
“Over the past year, as an advisor to our Board and the company, Christina Valauri has demonstrated deep commitment to excellence and the highest standards of ethical governance. This, paired with her insight into capital markets and deep background in research analysis, is a powerful combination to help ensure we make the best decisions for the company, our customers and our shareholders,” stated Board Chair, Sheryle Bolton.
Concurrently, Karen Drexler has tendered her resignation from the board effective September 30.
About Christina Valauri
Christina Valauri has served as a strategic advisor to the company since April 2023 and brings over 30 years of experience as a seasoned capital market professional with extensive analytical and management experience. Ms. Valauri has a proven track record as a senior healthcare analyst, US and Global Head of Equity Research, senior broker-dealer manager, strategic business consultant, and board director and advisor. As a managing director and senior manager within capital markets, she has successfully developed and executed transformational business strategies in the US and internationally to drive growth, and provide enhanced operating performance and comprehensive regulatory and supervisory oversight. She has held leadership roles at US and international firms, including as the Global Director of Research at Cantor Fitzgerald, and senior research management roles at Credit Lyonnais, ING, and Natixis.
Her career in equity securities research expands the Tivic boards’ deep expertise in pharmaceutical, biotech, and med-tech industries. She has extensive experience identifying and analyzing the commercial potential of breakthrough innovations, as well as mentoring and advising C-suite teams of private and public early-stage healthcare companies through product development, regulatory, go-to-market strategies, potential mergers and acquisitions, and IPOs.
Christina Valauri currently serves as an Entrepreneur in Residence at Weill Cornell Medicine BioVenture eLab, where she applies her skills and experience in life sciences and business. She supports and facilitates the organization’s mission to foster an entrepreneurial ecosystem related to the innovations of researchers and clinicians. Ms. Valauri is the founder and CEO of Sagestone Advisory, LLC., and also serves as a senior advisor with Hanover International, Inc. and Astia.org. She has been recognized by The Wall Street Journal’s “Best on The Street” All-Star Analyst Survey and has received the Award for Excellence in Medical Education Public Affairs – Association of American Medical Colleges. Ms. Valauri earned her BA in Biology from Reed College and an MBA from Cornell University.
About Tivic Health
Civic Health is a commercial health tech company advancing the field of bioelectronic medicine. Civic Health’s patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Civic Health’s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic Health’s first commercial product ClearUP is an FDA-approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors.
For more information: https://tivichealth.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
